4-(4'-carbomethoxyphenyl)cyclohexanone | 137464-98-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4'-carbomethoxyphenyl)cyclohexanone
• 英文别名: methyl 4-(4-oxocyclohexyl)benzoate；4-(4-oxocyclohexyl)benzoic acid methyl ester
• CAS: 137464-98-3
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: KIEGVTHKDIIVTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4'-carbomethoxyphenyl)cyclohexanone 在 甲酸 、 双氧水 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以48%的产率得到methyl 4-(4,4-dihydroperoxycyclohexyl)benzoate
  参考文献：
  名称：

  Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria

  摘要：

  A series of aryl carboxamide and benzylamino dispiro 1,2,4,5-tetraoxane analogues have been designed and synthesized in a short synthetic sequence from readily available starting materials. From this series of endoperoxides, molecules with in vitro IC50s versus Plasmodium falciparum (3D7) as low as 0.84 nM were identified. Based on an assessment of blood stability and in vitro microsomal stability, N205 (10a) was selected for rodent pharmacokinetic and in vivo antimalarial efficacy studies in the mouse Plasmodium berghei and Plasmodium falciparum Pf3D70087/N9 severe combined immunodeficiency (SCID) mouse models. The results indicate that the 4-benzylamino derivatives have excellent profiles with a representative of this series, N205, an excellent starting point for further lead optimization studies. (C) 2018 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2018.05.006
• 作为产物：
  描述：

  1,4-二氧杂螺[4.5]癸-7-烯-8-基三氟甲磺酸酯 在 盐酸 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium 10% on activated carbon 、 氢气 、 cesium fluoride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙酸乙酯 为溶剂， 20.0~90.0 ℃ 、310.27 kPa 条件下， 反应 45.0h， 生成 4-(4'-carbomethoxyphenyl)cyclohexanone
  参考文献：
  名称：

  NOVEL ORGANIC COMPOUND, NEAR-INFRARED FLUORESCENT CONSTANT MEDIUM CONTAINING SAME, AND METHOD FOR NANO-GRANULATING CONSTANT MEDIUM

  摘要：

  本发明涉及一种新型的有机化合物，含有该化合物的近红外荧光恒定介质，以及用于纳米粒化该恒定介质的方法。

  公开号：

  US20180327357A1

文献信息

• 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267689A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• DIACYLETHYLENEDIAMINE COMPOUND
  申请人：Kawano Tomoaki

  公开号：US20120046292A1

  公开（公告）日：2012-02-23

  [Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

  提供一种作为抗肥胖剂的化合物。现发明人调查了一种具有DGAT1抑制作用的化合物，该化合物有望成为治疗肥胖、2型糖尿病、脂肪肝以及与这些疾病相关的疾病的药物组合物的有效成分，并且他们发现了本发明的二酰乙二胺化合物具有出色的DGAT1抑制作用，从而完成了本发明。也就是说，本发明的二酰乙二胺化合物具有DGAT1抑制作用，因此可用作预防和/或治疗肥胖、2型糖尿病、脂肪肝以及与这些疾病相关的药物。
• Cyclized 5,10-dideazaaminopterin compounds
  申请人：——

  公开号：US05077404A1

  公开（公告）日：1991-12-31

  5,10-Dialkyl substituted 5,10-dideazaaminopterins and a cyclized derivative thereof are disclosed as potent antineoplastic agents. Also disclosed is an improved process for the preparation of 10-ethyl-10-deazaaminopterin using the intermediate methyl 4-[[2-(2,4-diamino-6-pteridinyl)-1-ethyl]ethenyl]benzoate.

  公开了5,10-二烷基取代的5,10-二脱氨基对氨基甲酸叶酸和其环化衍生物作为有效的抗肿瘤药物。还公开了一种改进的制备10-乙基-10-脱氨基对氨基甲酸叶酸的方法，该方法使用中间体甲基4-[[2-(2,4-二氨基-6-对二氨基嘌呤基)-1-乙基]乙烯基]苯甲酸酯。
• DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
  申请人：Sanofi

  公开号：US20130137691A1

  公开（公告）日：2013-05-30

  The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a —CH— group; X1 represents a nitrogen atom or a —CH═CH— group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1-C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a —(C3-C10)cycloalkyl- group; Y represents a —(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1-C6)alkoxy group; Z1 is absent or represents an —NH— function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.

  本发明涉及公式（I）的化合物： 其中： n等于0或1； D代表氧原子或键； W代表氮原子或—CH—基团； X1代表氮原子或—CH═CH—基团； X2代表氧原子或氮原子； X3代表氧原子或氮原子； X1、X2、X3中的一个不是氮原子，X2和X3同时不是氧原子； R1，R2不存在或代表（i）彼此独立的氢原子或（C1-C4）烷基，（ii）R1和R2可以与它们附着的碳原子形成—（C3-C10）环烷基-基团； Y代表—（C3-C10）环烷基-、芳基或芳氧基团，这些基团可以选择性地被一个或多个卤素原子或（C1-C6）烷氧基置换； Z1不存在或代表—NH—功能； Z2和Z3如本说明中所定义。 本发明还涉及制备公式（I）的化合物的方法、含有它们的组合物以及它们在治疗学中的应用。
• Liquid crystalline mixtures containing 3,4-difluorophenyl-substituted
  申请人：Hoffmann-La Roche Inc.

  公开号：US05185098A1

  公开（公告）日：1993-02-09

  Compounds of formula ##STR1## wherein Z is a single covalent bond or --CH.sub.2 CH.sub.2 --, and R.sup.1 is 1E-alkenyl with 2-12 carbon atoms, liquid crystalline mixtures containing them and their use for electro-optical purposes.

  该公式的化合物为##STR1##其中Z是单一共价键或--CH.sub.2 CH.sub.2 --，R.sup.1是具有2-12个碳原子的1E-烯基，包含它们的液晶混合物以及它们用于电光目的的用途。